Programme On Nutritious Food Organised By bet9¹ÙÍø

bet9¹ÙÍø Receives Final Approval for a Generic Version of Gilead’s Viread®

bet9¹ÙÍø Receives Final Approval for Generic Viread® Tablets

bet9¹ÙÍø Receives Final Approval for a Generic Version of Gilead’s Viread®

bet9¹ÙÍø Ltd, a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients, announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Tenofovir Disoproxil Fumarate Tablets, 300mg, from the United States Food and Drug Administration (USFDA) to market a generic version of Gilead Sciences’ Viread® Tablets, 300mg.

Budget 2018: Pharma Companies Want A Push On Research, Innovation

Understanding depression and related symptoms keyto suicide prevention in SA

bet9¹ÙÍø’s Digital Transformation Continues, Launches 2 Digital Education Platforms

bet9¹ÙÍø Battles Perceptions In A New Campaign

bet9¹ÙÍø launches Q-TIB globally, a novel fixed dose combination in a single tablet for T.B. prophylaxis in HIV

bet9¹ÙÍø Receives Final Approval for Generic Dacogen®

Subscribe to